SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant $extsf{ }$

Filed by a Party other than the Registrant \Box

Check the appropriate box:

- Preliminary Proxy Statement
- □ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- □ Definitive Proxy Statement
- Definitive Additional Materials
- □ Soliciting Material Pursuant to § 240.14a-12

AcelRx Pharmaceuticals, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box)

- \boxtimes No fee required.
- □ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - 1. Title of each class of securities to which transaction applies:
 - 2. Aggregate number of securities to which transaction applies:
 - 3. Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
 - 4. Proposed maximum aggregate value of transaction:
 - 5. Total fee paid:
- □ Fee paid previously with preliminary materials.
- □ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 - 6. Amount Previously Paid:
 - 7. Form, Schedule or Registration Statement No.:

8. Filing Party:

9. Date Filed:


*** Exercise Your *Right* to Vote *** Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on June 16, 2020

ACELRX PHARMACEUTICALS INC	Meeting Information Meeting Type: Annual Meeting For holders as of: April 20, 2020 Date: June 16, 2020 Time: 10:00 AM PDT Location: AceRx Pharmaceuticals, Inc. 351 Galveston Drive Redwood City, CA 94063 D E
Pharmaceuticals, Inc.	You are receiving this communication because you hold shares in the above named company. This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a
Investor Address Line 4 Investor Address Line 5 John Sample 1234 ANYWHERE STREET ANY CITY, ON A1A 1A1	paper copy (see reverse side). We encourage you to access and review all of the important
	Broadridge Internal Use Only Job # Envelope # Sequence # # of # Sequence #

0000459352_I RI.0.1.18

— Before You Vote —

How to Access the Proxy Materials



— How To Vote —

Please Choose One of the Following Voting Methods

Vote In Person: Many stockholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

Vote By Internet: To vote now by Internet, go to www.proxywote.com. Have the information that is printed in the box marked by the arrow \rightarrow [XXXX XXXX XXXX XXXX] available and follow the instructions.

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

Internal Use Only

			Voting	items		
71	Bernd		D			

The Board of Directors recommends you vote FOR the following:

1. Election of Directors

Nominees

01 Howard B. Rosen 02 Mark Wan

The Board of Directors recommends you vote FOR the following proposals:

- To ratify the selection by the Audit Committee of the Board of Directors of OUM & Co. LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020.
- To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the accompanying proxy statement.
- 4. To approve the Company's 2020 Equity Incentive Plan.
- 5. To approve the Company's Amended and Restated 2011 Employee Stock Purchase Plan.

NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

0000459352_3 R1.0.1.18

\rightarrow	0000 0000 0000 0000

	B R C D E		

Broadridge Internal Use Only
XXXXXXXXXXX
XXXXXXXXXXXX
Cusip
dol
Envelope #
Sequence #
of # Sequence



NAME	
THE COMPANY NAME INC COMMON THE COMPANY NAME INC CLASS A THE COMPANY NAME INC CLASS B THE COMPANY NAME INC CLASS C THE COMPANY NAME INC CLASS D THE COMPANY NAME INC CLASS F THE COMPANY NAME INC CLASS F THE COMPANY NAME INC CLASS F THE COMPANY NAME INC 401 K	123,456,789,012.12345 123,456,789,012.12345 123,456,789,012.12345 123,456,789,012.12345 123,456,789,012.12345 123,456,789,012.12345 123,456,789,012.12345 123,456,789,012.12345

RI.0.1.18		
000459352_4		Broadridge Internal Use Only
0	THIS SPACE RESERVED FOR SIGNATURES IF APPLICABLE	Job # Envelope # Sequence # # of # Sequence #